CVE-2024-24812

Frappe Authenticated Reflected Cross site scripting (XSS) in portal pages

Description

Frappe is a full-stack web application framework that uses Python and MariaDB on the server side and a tightly integrated client side library. Prior to versions 14.59.0 and 15.5.0, portal pages are susceptible to Cross-Site Scripting (XSS) which can be used to inject malicious JS code if user clicks on a malicious link. This vulnerability has been patched in versions 14.59.0 and 15.5.0. No known workarounds are available.

Category

5.4
CVSS
Severity: Medium
CVSS 3.1 •
EPSS 0.33%
Vendor Advisory github.com
Affected: frappe frappe
Published at:
Updated at:

References

Link Tags
https://github.com/frappe/frappe/security/advisories/GHSA-7p3m-h76m-hg9v vendor advisory
https://github.com/frappe/frappe/releases/tag/v14.59.0 release notes
https://github.com/frappe/frappe/releases/tag/v15.5.0 release notes

Frequently Asked Questions

What is the severity of CVE-2024-24812?
CVE-2024-24812 has been scored as a medium severity vulnerability.
How to fix CVE-2024-24812?
To fix CVE-2024-24812, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2024-24812 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2024-24812 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2024-24812?
CVE-2024-24812 affects frappe frappe.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.